Table 2.
Study participants classified by strata of index creatinine and Stage of CKD using abbreviated MDRD equation
| Serum creatinine at cohort entry
|
||||||||
|---|---|---|---|---|---|---|---|---|
| Less than or equal to 1.3 mg/dl | 1.4 to 1.6 mg/dl | 1.7 to 2.1 mg/dl | Greater or equal to 2.2 mg/dl | |||||
|
| ||||||||
| CKD Stage* | CKD Stage* | CKD stage* | CKD stage* | |||||
|
| ||||||||
| 3a | 3b/4/5 | 3a | 3b/4/5 | 3a | 3b/4/5 | 3a | 3b/4/5 | |
|
| ||||||||
| Sample Size (Row %) | 12027 (98.7%) | 160 (1.3%) | 22624 (89.1%) | 2771 (10.9%) | 2527 (15.2%) | 14126 (84.8%) | 0 | 15908 (100%) |
|
| ||||||||
| Age | ||||||||
| ≤63 years | 1940 (16.1%) | 34 (21.3%) | 6125 (27.1%) | 99 (3.6%) | 1123 (44.4%) | 2855 (20.2%) | 02 | 5684 (35.7%) |
| 64–73 years | 3944 (32.8%) | 33 (20.6%) | 6619 (29.3%) | 81 (2.9%) | 556 (22.0%) | 3404 (24.1%) | 0 | 3841 (24.1%) |
| 74–80 years | 3393 (28.2%) | 21 (13.1%) | 5572 (24.6%) | 1151 (41.5%) | 448 (17.7%) | 4043 (28.6%) | 0 | 3510 (22.1%) |
| ≥81 years | 2750 (22.9%) | 72 (45.0%) | 4308 (19.0%) | 1440 (52.0%) | 400 (15.8%) | 3824 (27.1%) | 0 | 2873 (18.1%) |
|
| ||||||||
| Gender | ||||||||
| Male | 10725 (89.2%) | 0 | 22567 (99.7%) | 2432 (87.8%) | 2527 (100.0%) | 13921 (98.5%) | 02 | 15688 (98.6%) |
| Female | 1302 (10.8%) | 160 (100.0%) | 57 (0.3%) | 339 (12.2%) | 0 | 205 (1.5%) | 0 | 220 (1.4%) |
|
| ||||||||
| Ethnicity | ||||||||
| Caucasian | 11814 (98.2%)1 | 160 (100.0%) | 19901 (88.0%) | 2731 (98.6%) | 129 (5.1%) | 12695 (89.9%) | 02 | 10678 (67.1%) |
| African American | 84 (0.7%) | 0 | 2501 (11.1%) | 18 (0.6%) | 2390 (94.6%) | 1272 (9.0%) | 0 | 5004 (31.5%) |
| Other | 129 (1.1%) | 0 | 222 (1.0%) | 22 (0.8%) | 8 (0.3%) | 159 (1.1%) | 0 | 226 (1.4%) |
|
| ||||||||
| Diabetes | ||||||||
| Yes | 4775 (39.7%)1 | 57 (35.6%) | 10701 (47.3%) | 1135 (41.0%) | 1317 (52.1%)1 | 7648 (54.1%) | 02 | 9767 (61.4%) |
| No | 7252 (60.3%) | 103 (64.4%) | 11923 (52.7%) | 1636 (59.0%) | 1210 (47.9%) | 6478 (45.9%) | 0 | 6141 (38.6%) |
|
| ||||||||
| CVD | ||||||||
| Yes | 5510 (45.8%)1 | 160 (45.6%) | 11278 (49.8%) | 1560 (56.3%) | 1177 (46.6%) | 8402 (59.5%) | 02 | 9361 (58.8%) |
| No | 6517 (54.2%) | 87 (54.4%) | 11346 (50.2%) | 1211 (43.7%) | 1350 (53.4%) | 5724 (40.5%) | 0 | 6547 (41.2%) |
|
| ||||||||
| Malignancy | ||||||||
| Yes | 3323 (27.6%)1 | 39 (75.6%) | 6258 (27.7%) | 843 (30.4%) | 661 (26.2%) | 4137 (29.3%) | 02 | 4057 (25.5%) |
| No | 8704 (72.4%) | 121 (75.6%) | 16366 (72.3%) | 1928 (69.6%) | 1866 (73.8%) | 9989 (70.7%) | 0 | 11851 (74.5%) |
|
| ||||||||
| Hospitalization | ||||||||
| 1 (only index hosp.) | 8060 (67.0%)1 | 112 (70.0%) | 14648 (64.7%) | 1736 (62.6%) | 1583 (62.6%) | 8513 (60.3%) | 02 | 8313 (52.3%) |
| >1 (subsequent hosp.) | 3967 (33.0%) | 48 (30.0%) | 7976 (35.3%) | 1035 (37.4%) | 944 (37.4%) | 5613 (39.7%) | 0 | 7595 (47.7%) |
|
| ||||||||
| ACE or ARB | ||||||||
| Yes | 7509 (62.4%)1 | 103 (64.4%) | 15347 (67.8%) | 1798 (64.9%) | 1751 (69.3%)1 | 9832 (69.6%) | 02 | 9644 (60.6%) |
| No | 4518 (37.6%) | 57 (35.6%) | 7277 (32.2%) | 973 (35.1%) | 776 (30.7%) | 4294 (30.4%) | 0 | 6264 (39.4%) |
|
| ||||||||
| Charlson Comorbidity | ||||||||
| 0 | 4979 (41.4%)1 | 64 (40.0%) | 9226 (40.8%) | 991 (35.8%) | 1188 (47.0%) | 5099 (36.1%) | 02 | 6108 (38.4%) |
| 1 | 4606 (38.3%) | 63 (39.4%) | 8587 (38.0%) | 1119 (40.4%) | 841 (33.3%) | 5465 (38.7%) | 0 | 5822 (36.6%) |
| ≥2 | 2442 (20.3%) | 33 (20.6%) | 4811 (21.3%) | 661 (23.9%) | 498 (15.2%) | 3562 (25.2%) | 0 | 3978 (25.0%) |
*
CKD Stage based on estimated GFR using modified MDRD equation on Cr obtained at cohort entry.
1
CKD stage definitions in eGFR (mL/min/1.73m2): stage 3a, eGFR 45–59; stage 3b, eGFR 30–44; stage 4, eGFR 15–29; stage 5, eGFR <15
2
Denotes unable to determine p-value because of empty cells in contingency table. All other p-values significant (p < 0.05).